TLDR: Arena BioWorks has launched as a biomedical research institute that will create for-profit biotech companies to develop lifesaving therapeutics. The company, which is supported by co-founders Harvard University scientist Stuart Schreiber, former Bain Capital Co-Chair Steve Paglicua and Tom Cahill of venture capital firm Newpath Partners, will use private funding to quickly translate insights into discovery. Use of drug discovery platforms will also be supported through preclinical studies and beyond.
Accelerating Insight to Therapeutics: Introducing Arena BioWorks’ Biomedical Breakthroughs
Latest from Blog
Venture Capital News: Avail, M^0, Sandbox Secure Millions in Funding
VC Roundup Summary TLDR: Key Points: 21 startups raised $399.7 million in VC funding in the blockchain space from June 2 to June 8. Avail secured $43 million, M^0 raised $35 million,
American Tech Industry Pushes Chinese VC to Liquidate Investments
TLDR: US tech sector pressures Chinese venture capital to divest Chinese venture capital firms facing pressure to divest from US tech sector due to national security concerns In a move driven by
Middle East’s Position in Global AI Funding Race
TLDR: Global venture capital funds are investing in AI in the Middle East, showing solid interest in the region’s technology industry and potential. The UAE and Saudi Arabia are leading the AI
Unveiling the Power of Venture Capital in Driving Innovation
TLDR: FICCI Ladies Organisation (FLO) Hyderabad organized a session on the role of venture capitalists in innovation. Priya Gazdar highlighted the history of venture capitalism, emphasizing the importance of behavior in founders
Nascent Ventures amasses 445 billion PEPE coins in savvy maneuver
TLDR: Nascent Ventures acquires over 445 billion PEPE coins worth $5.48 million in a strategic move. The strategic investment by Nascent highlights their optimistic stance on PEPE’s prospects and solidifies PEPE’s status